List of Excipients in Branded Drug METHADONE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	METHADONE HYDROCHLORIDE	methadone hydrochloride	0054-4570	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	METHADONE HYDROCHLORIDE	methadone hydrochloride	0054-4570	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	METHADONE HYDROCHLORIDE	methadone hydrochloride	0054-4570	STARCH, CORN
STAT Rx USA LLC	METHADONE HYDROCHLORIDE	methadone hydrochloride	16590-689	CELLULOSE, MICROCRYSTALLINE

Generic Drugs Containing METHADONE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA	methadone hydrochloride	0054-0392	ANHYDROUS CITRIC ACID
Hikma Pharmaceuticals USA	methadone hydrochloride	0054-0392	CHERRY
Hikma Pharmaceuticals USA	methadone hydrochloride	0054-0392	D&C RED NO. 33
Hikma Pharmaceuticals USA	methadone hydrochloride	0054-0392	FD&C RED NO. 40

What are the Most Frequently-Used Excipients in METHADONE HYDROCHLORIDE?

# Of NDCs	Excipient
7	ALCOHOL
12	ANHYDROUS CITRIC ACID
1	ANHYDROUS LACTOSE
7	BENZOIC ACID

Methadone Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: July 31, 2026

Methadone hydrochloride is a mature, off-patent opioid available in tablets, oral solutions and concentrates, and injectable products. The commercial opportunity is concentrated in formulation differentiation rather than new-molecule exclusivity. Priority areas include dose accuracy, tamper resistance, pediatric and institutional safety, preservative systems, palatability, packaging, and supply-chain reliability.

Methadone products face unusually high regulatory and operational barriers. Methadone for opioid use disorder is dispensed primarily through federally regulated opioid treatment programs, while methadone for pain is subject to Schedule II controls and opioid-labeling requirements.[1][2] Excipients can improve product performance, but they do not eliminate controlled-substance, diversion, or abuse-liability obligations.

What products contain methadone hydrochloride?

Methadone hydrochloride is marketed in several dosage forms with different excipient requirements.

Dosage form	Typical use	Core excipient priorities	Commercial differentiation
Immediate-release tablets	Pain management; institutional use	Compression, stability, taste masking, swallowability	Lower-cost supply, scoring, packaging, dose flexibility
Oral solution or concentrate	Opioid use disorder and pain	Solubility, preservative system, viscosity, palatability, dose-measurement accuracy	Unit-dose packaging, closed-system dispensing, reduced diversion risk
Injection	Acute pain and hospital use	Sterility, isotonicity, preservative selection, container compatibility	Reliable supply, ready-to-administer presentations, stability
Extemporaneous or pharmacy-compounded liquid	Limited institutional or specialty use	Vehicle compatibility, uniformity, microbial control	Specialty pharmacy and hospital procurement
Novel modified-release or abuse-deterrent product	Potential future use	Release control, tamper resistance, dose dumping prevention	Higher regulatory and development burden

The FDA-approved product landscape includes methadone hydrochloride tablets, oral solutions and injections. Product-specific inactive ingredients must be verified against the current package insert and FDA Inactive Ingredient Database because excipient composition varies by manufacturer and strength.[3][4]

What excipients are used in methadone hydrochloride tablets?

Methadone hydrochloride tablets generally use conventional solid-dose excipients. Depending on the manufacturer and strength, these may include fillers, binders, disintegrants, lubricants, glidants, colorants and coating materials.

Tablet excipient functions

Excipient function	Development objective	Methadone-specific consideration
Diluent or filler	Achieve tablet mass and content uniformity	Low-dose strengths require careful blend uniformity
Binder	Improve granule or tablet mechanical strength	Excessive binding can slow disintegration
Disintegrant	Support rapid tablet breakup	Must be balanced against compression and storage stability
Lubricant	Prevent sticking and improve ejection	Hydrophobic lubricants can affect dissolution
Glidant	Improve powder flow	Important for high-throughput, multi-strength production
Colorant	Strength identification	Reduces medication-selection errors in institutional settings
Film coat	Improve handling and swallowability	Adds manufacturing steps and potential dissolution variables

Low-dose methadone tablets create a content-uniformity challenge because the active pharmaceutical ingredient represents a small fraction of total tablet mass. Direct compression may be attractive for simplicity, but wet or dry granulation can provide better segregation control when powder-flow properties are unfavorable.

The highest-value formulation work is likely to involve robust low-dose uniformity, tablet identification, packaging compatibility and reduced breakage during automated dispensing. These improvements can support procurement decisions even when the product has no meaningful patent protection.

What excipients are used in methadone oral solutions and concentrates?

Liquid methadone products require a different excipient strategy. The main technical issues are active concentration, chemical stability, microbial control, palatability, dose measurement and compatibility with dispensing equipment.

Potential excipient categories include:

• Purified water as the principal vehicle.
• Acidity regulators or buffers.
• Chelating agents where justified by stability data.
• Preservatives for multidose products.
• Sweeteners and flavors for palatability.
• Viscosity modifiers to reduce splashing and improve dosing control.
• Colorants for product identification.
• Packaging components that limit adsorption, leaching and dosing errors.

Methadone hydrochloride is highly soluble in water, which supports oral liquid development. The commercial problem is not basic solubilization. It is maintaining concentration uniformity across the shelf life while controlling microbial risk and making the product difficult to misuse or inaccurately dispense.

A formulation should be evaluated for:

1. Assay and related substances over the proposed shelf life.
2. Uniformity from the first to the last dose in a multidose container.
3. Compatibility with oral syringes, dosing cups, automated dispensing systems and clinic equipment.
4. Preservative effectiveness where a multidose presentation is used.
5. Container-closure integrity.
6. Taste and odor, particularly for pediatric, chronic-use or take-home presentations.
7. Risk of accidental ingestion by children.

A more viscous formulation may reduce spillage, but excessive viscosity can impair syringe accuracy and increase residual drug in dosing equipment. Unit-dose packaging can improve operational control but may increase packaging cost and waste.

Which excipient strategies offer the strongest commercial opportunity?

The most practical opportunities are incremental products that address measurable operating problems.

Unit-dose and closed-system oral liquids

Unit-dose cups, oral syringes or sealed sachets can reduce dosing errors and unauthorized transfer. These presentations are relevant to opioid treatment programs, correctional facilities, hospitals, long-term-care operators and specialty pharmacies.

The value proposition is operational rather than pharmacological:

• Less manual measurement.
• Better chain-of-custody documentation.
• Lower risk of container contamination.
• Easier reconciliation of administered doses.
• Reduced opportunity for diversion during transport or storage.

The principal limitations are packaging cost, filling-line complexity and the need to demonstrate container compatibility.

Palatable, lower-sugar oral formulations

Methadone oral liquids may be administered repeatedly over long periods. A formulation with controlled sweetness, reduced sugar or an alternative sweetener system could target patients with diabetes, dental-risk concerns or intolerance to conventional flavors.

The development package should evaluate taste masking without creating a formulation that is attractive to children. Flavor selection must be considered alongside accidental-ingestion risk and abuse-deterrence objectives.

Pediatric and adolescent presentations

Methadone is used in carefully controlled clinical settings involving neonatal abstinence and pediatric pain, but pediatric formulations require high attention to concentration, dosing devices and accidental exposure. A commercially viable product would need:

• Low-volume dosing at clinically relevant strengths.
• A calibrated oral syringe.
• Clear concentration labeling.
• Child-resistant packaging.
• Low-transfer packaging with limited residual volume.
• Stability after opening.

A pediatric product would face a narrow market and substantial safety scrutiny. Its opportunity is strongest where it reduces hospital preparation and dose-measurement burden.

Abuse-deterrent excipient systems

Abuse-deterrent tablets or liquids could use physical barriers, gelling agents, aversive systems or tamper-resistant packaging. The FDA evaluates abuse-deterrent claims through a product-specific framework, including laboratory, pharmacokinetic and human abuse-potential evidence where applicable.[5]

For methadone, an abuse-deterrent strategy has a difficult risk-benefit profile. Methadone has a long half-life, respiratory-depression risk and established diversion concerns. A formulation that can be manipulated into a concentrated or rapidly available dose could create serious safety risks. Packaging-based deterrence may therefore be more commercially practical than a complex matrix tablet.

What FDA regulatory status applies to methadone hydrochloride?

Methadone hydrochloride is an FDA-approved active ingredient with multiple approved dosage forms. Regulatory requirements depend on the indication and formulation.

Regulatory issue	Commercial implication
ANDA pathway for eligible generic products	Limits reliance on clinical efficacy development for conventional products
Schedule II controlled substance	Requires DEA registration, security controls, inventory procedures and recordkeeping
Opioid labeling requirements	Increases labeling, risk-management and promotional constraints
Opioid treatment program rules	Restricts the channel for methadone used in opioid use disorder
Oral-liquid concentration differences	Creates medication-error and labeling risk
Novel excipient or new route	May require additional toxicology, clinical or pharmacology data
Abuse-deterrent claim	Requires evidence beyond conventional bioequivalence
New indication or modified-release product	May require a 505(b)(2) or NDA strategy

Methadone for opioid use disorder is not distributed through ordinary retail channels in the same manner as most chronic medicines. Federal opioid treatment program rules govern dispensing and administration, with state-level requirements also affecting operations.[2] A formulation designed for clinics must fit observed dispensing workflows, not only standard retail pharmacy practices.

What patents protect methadone hydrochloride products?

The original methadone hydrochloride compound and conventional dosage forms are long off patent. There is no biosimilar pathway because methadone hydrochloride is a synthetic small molecule, not a biologic.

IP category	Current relevance
Methadone hydrochloride compound patent	Historical; expired
Conventional tablet composition	Generally vulnerable to generic competition
Conventional oral solution	Generally vulnerable to generic competition
Conventional injection	Generally vulnerable to generic competition
New excipient combination	Potential formulation patent if technically distinctive
Abuse-deterrent dosage form	Potential composition and method patents
Packaging and dispensing system	Potential device or method claims
Manufacturing process	Potential process patent or trade secret
Method-of-use patent	Possible for a new indication or dosing regimen
Biosimilar exclusivity	Not applicable

The Orange Book should be reviewed for current patent listings and regulatory exclusivity associated with each reference product.[6] Because methadone products are old and genericized, the commercial protection for a new product is more likely to come from formulation patents, device claims, manufacturing know-how, regulatory differentiation or supply contracts than from the active ingredient.

A defensible formulation patent would need to claim more than the routine use of a known filler, preservative or flavor. Stronger claims could focus on a defined excipient ratio, validated stability profile, controlled-release mechanism, tamper-resistance architecture, container system or manufacturing process that produces a non-obvious technical result.

When does methadone hydrochloride lose exclusivity?

Methadone hydrochloride has already lost basic compound exclusivity. Conventional generic entry is established across the principal dosage forms.

There is no conventional small-molecule exclusivity timeline comparable to a recently approved branded drug. Any future exclusivity would depend on a new product, indication, formulation or delivery technology. Potential pathways include:

• Five-year new chemical entity exclusivity, generally unavailable for an old active ingredient.
• Three-year clinical-investigation exclusivity for certain new applications or formulations supported by required clinical studies.
• Orphan-drug exclusivity if statutory orphan criteria and approval requirements are satisfied.
• Pediatric exclusivity, which can extend existing exclusivity or patent terms after a qualifying FDA request.
• Patent protection for a genuinely new formulation, process or device.

The actual availability of these protections depends on the regulatory classification and development package. A reformulated methadone product should not be assumed to qualify for new chemical entity exclusivity.

Are there Paragraph IV challenges involving methadone hydrochloride?

Paragraph IV litigation is not the principal commercial issue for the legacy methadone market because the core products are already subject to extensive generic competition. A Paragraph IV dispute could arise if a company obtains listing for a new formulation or method-of-use patent in the Orange Book.

The principal litigation risks for a new methadone product would be:

1. ANDA applicants challenging formulation or method patents.
2. Patent-owner suits filed within the statutory 45-day period after a Paragraph IV notice.
3. Regulatory disputes over whether a listed patent properly claims the approved product.
4. Product-liability claims involving concentration errors, accidental ingestion or diversion.
5. Trade-secret disputes over manufacturing or packaging systems.

Generic launch timing would depend on patent certification, litigation, regulatory exclusivity, settlement terms and any court-imposed stay. For an unpatented conventional formulation, the launch risk is immediate once FDA approval and controlled-substance supply arrangements are in place.

What manufacturing and IP barriers affect methadone excipient products?

Manufacturing barriers are more important than active-ingredient patent barriers.

Oral liquids

Key barriers include:

• Accurate filling at low and high volumes.
• Preservative effectiveness.
• Container compatibility.
• Cleaning validation for a potent opioid.
• Prevention of cross-contamination.
• Controlled-substance inventory reconciliation.
• Stability after opening.
• Reliable sourcing of flavors, sweeteners and packaging components.

Tablets

Important barriers include:

• Low-dose content uniformity.
• Segregation control.
• Multi-strength line clearance.
• Robustness during transport.
• Color and imprint differentiation.
• Containment during weighing, blending and compression.

Injectable products

Injectables require validated sterilization or aseptic processing, particulate control, container-closure integrity and compatibility with elastomers and glass. A shortage-resistant injectable supply can have commercial value because hospitals prioritize dependable availability for controlled medicines.

Manufacturing know-how can be protected through trade secrets even where patent protection is weak. A process that consistently achieves low-dose uniformity, low residual drug in equipment and validated cleaning performance may create a meaningful procurement advantage.

Which companies are challenging or competing with methadone products?

Competition is primarily generic and supply-based. The relevant competitors include manufacturers of methadone hydrochloride tablets, oral solutions, concentrates and injections, as well as compounders and institutional pharmacy suppliers where legally permitted.

The competitive landscape is shaped by:

• FDA approval status.
• DEA quota and controlled-substance compliance.
• Product availability and shortage history.
• Concentration and dosage-form range.
• Packaging options.
• Institutional contracting.
• Ability to supply opioid treatment programs.
• Quality-system performance.

No biosimilar competitors exist. Buprenorphine products compete with methadone in opioid-use-disorder treatment, but they are therapeutic alternatives rather than methadone generics. Buprenorphine has different formulation, regulatory and dispensing characteristics, which may make it more attractive in office-based treatment settings.[7]

How does methadone compare with buprenorphine for formulation opportunity?

Factor	Methadone hydrochloride	Buprenorphine
Molecular class	Synthetic opioid	Partial opioid agonist
Biosimilar pathway	Not applicable	Not applicable
Core market	Opioid treatment programs and pain	Opioid use disorder and pain
Main dosage forms	Tablets, oral liquids, injection	Sublingual, buccal, implant and injection products
Excipient opportunity	Dosing control, palatability, packaging, tamper resistance	Mucoadhesion, rapid dissolution, depot delivery, taste masking
Dispensing model	Highly regulated OTP channel for OUD	Broader treatment settings, subject to applicable rules
Generic pressure	High for conventional products	High in mature sublingual categories
Product differentiation	Operational and safety-focused	Delivery technology and adherence-focused

Methadone has a stronger opportunity for institutional workflow products. Buprenorphine has broader scope for novel delivery systems, but competition and patent density are generally greater in advanced formulations.

What licensing deals and commercial models are available?

Methadone excipient technology is more likely to be licensed through platform or product-development agreements than through legacy active-ingredient licenses.

Potential structures include:

• Exclusive regional rights to a novel oral-liquid formulation.
• Supply agreements with opioid treatment program operators.
• Contract manufacturing partnerships for controlled-substance liquids.
• Packaging licenses for unit-dose or tamper-resistant systems.
• Co-development agreements for a 505(b)(2) product.
• Technology-transfer agreements covering cleaning, containment and filling processes.
• Hospital and correctional-health procurement contracts.

A licensing valuation should focus on approval probability, channel access, supply reliability, patent term, formulation performance and controlled-substance operating capability. A technically strong formulation without DEA-compliant manufacturing and distribution infrastructure has limited commercial value.

What generic launch risks exist for a new methadone formulation?

A new product faces several launch scenarios.

Scenario	Likely outcome
Conventional tablet with routine excipients	Rapid generic competition and low pricing power
Oral liquid with improved flavor only	Limited differentiation unless tied to adherence or safety data
Unit-dose liquid with validated workflow benefits	Moderate institutional opportunity
Child-resistant, low-residual packaging	Potential procurement advantage; patentability depends on design
Abuse-deterrent formulation	Higher development cost and regulatory evidence burden
Modified-release product	Greater pricing potential but substantial clinical and abuse-liability risk
Shortage-resistant injectable	Commercial value depends on manufacturing reliability and contracts

The most credible near-term strategy is a differentiated oral liquid or packaging system with measurable reductions in dosing error, contamination, diversion or clinic labor. A conventional excipient substitution alone is unlikely to sustain premium pricing.

Key Takeaways

• Methadone hydrochloride is an off-patent, genericized small molecule with no biosimilar opportunity.
• Excipient strategy should focus on oral-liquid stability, dose accuracy, palatability, child safety, packaging and institutional workflow.
• Unit-dose and closed-system presentations have stronger commercial logic than routine tablet reformulation.
• Abuse-deterrent claims require a substantial FDA evidence package and may be less practical than packaging-based controls.
• Methadone for opioid use disorder is tied to opioid treatment program regulation, limiting ordinary retail distribution.
• Formulation patents, device claims, process patents and trade secrets are more relevant than compound patents.
• The strongest competitive advantage is likely to come from reliable controlled-substance manufacturing, regulatory compliance and institutional supply contracts.
• Paragraph IV litigation and settlement activity are secondary risks unless a new methadone formulation creates Orange Book-listed patents.
• Commercial value depends on operational performance and channel access more than on the choice of a conventional filler, binder or flavor.

FAQs

Can a new excipient create patent protection for methadone hydrochloride?

Yes, but routine substitution of a known excipient generally provides weak protection. A stronger patent position requires a defined formulation or process with a non-obvious technical result, such as improved stability, controlled release, reduced dose dumping or validated tamper resistance.

Is methadone hydrochloride eligible for a biosimilar application?

No. Methadone hydrochloride is a synthetic small-molecule drug. Comparable products are generally pursued through abbreviated new drug applications or, for certain reformulations, a 505(b)(2) application.

Which methadone dosage form has the greatest excipient opportunity?

Oral liquids and concentrates have the strongest opportunity because excipients can affect palatability, viscosity, preservative performance, dosing accuracy and container compatibility. Unit-dose packaging can increase differentiation further.

Can an abuse-deterrent methadone product obtain premium pricing?

Potentially, but premium pricing would require regulatory-recognized abuse-deterrent performance, reliable payer or institutional demand and evidence that the added cost reduces diversion or medication error. Packaging-based deterrence may be more commercially feasible than a complex tablet matrix.

What is the main commercial barrier to launching a generic methadone liquid?

The principal barriers are controlled-substance compliance, reliable API supply, validated cleaning and containment, preservative and stability performance, accurate filling, packaging compatibility and access to opioid treatment program or institutional purchasers.

References

1. U.S. Food and Drug Administration. (2024). Methadone hydrochloride prescribing information. FDA.
2. Substance Abuse and Mental Health Services Administration. (2024). Federal guidelines for opioid treatment programs. U.S. Department of Health and Human Services.
3. U.S. National Library of Medicine. (2024). DailyMed: Methadone hydrochloride products. National Institutes of Health.
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.
5. U.S. Food and Drug Administration. (2020). Abuse-deterrent opioids: Evaluation and labeling. FDA.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
7. U.S. Food and Drug Administration. (2024). Medication-assisted treatment of opioid use disorder. FDA.